Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

HLA typing; DR/DQ, single antigen

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

Human leukocyte antigen (HLA) typing is a laboratory procedure that focuses on identifying specific antigens known as DR and DQ antigens. These antigens are crucial for understanding an individual's immune response and are particularly significant in the context of organ transplantation and disease susceptibility. The HLA typing process involves testing for specific HLA alleles, which can reveal whether a person is predisposed to certain diseases or if they are a suitable match for a stem cell, bone marrow, or solid organ transplant. HLA antigens are categorized into two main classes: Class I and Class II alleles. Among the Class II alleles, HLA-DQ2 and HLA-DQ8 are commonly tested in patients who exhibit symptoms of celiac disease or have a family history of this condition. Additionally, HLA-DR15 and HLA-DQ6 are utilized to help distinguish narcolepsy from other sleep-related disorders. The tests for Class II HLA-DR DNA typing and HLA-DQ DNA typing are instrumental in identifying risks for various autoimmune disorders and ensuring compatibility between potential organ donors and recipients. For coding purposes, the CPT® Code 86816 is designated for typing a single antigen, while CPT® Code 86817 is used when multiple HLA antigens are analyzed.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

HLA typing is indicated for several specific conditions and scenarios, particularly in the context of disease susceptibility and transplantation compatibility. The following are the primary indications for performing HLA typing:

  • Celiac Disease - Testing for HLA-DQ2 and HLA-DQ8 is performed in symptomatic patients or those with a family history of celiac disease to assess susceptibility.
  • Narcolepsy - HLA-DR15 and HLA-DQ6 typing is utilized to differentiate narcolepsy from other sleep disorders, aiding in accurate diagnosis.
  • Autoimmune Disorders - HLA-DR and HLA-DQ typing is conducted to identify susceptibility to various autoimmune conditions.
  • Transplant Compatibility - HLA typing is essential for determining tissue compatibility between potential organ, stem cell, or bone marrow donors and recipients.

2. Procedure

The procedure for HLA typing involves several key steps that ensure accurate identification of the specific antigens. The following outlines the procedural steps involved:

  • Sample Collection - A blood sample is collected from the patient, which serves as the source of DNA for HLA typing. This sample is typically drawn from a vein in the arm using standard venipuncture techniques.
  • DNA Extraction - The collected blood sample undergoes a process of DNA extraction, where the cellular components are separated to isolate the DNA. This step is crucial for obtaining a pure sample that can be analyzed for HLA antigens.
  • Amplification of HLA Genes - Polymerase chain reaction (PCR) techniques are employed to amplify the specific regions of the HLA genes that correspond to the DR and DQ antigens. This amplification is necessary to ensure that there is enough genetic material for accurate typing.
  • Typing Analysis - The amplified DNA is then analyzed using various methods, such as sequence-specific oligonucleotide probes or next-generation sequencing, to identify the presence of specific HLA alleles. This analysis determines the individual's HLA type.
  • Result Interpretation - The results of the HLA typing are interpreted by a qualified laboratory professional, who will provide a report detailing the specific HLA antigens identified in the sample.

3. Post-Procedure

After the HLA typing procedure, there are typically no specific post-procedure care requirements for the patient, as the process is minimally invasive and involves only a blood draw. Patients may resume normal activities immediately following the sample collection. The results of the HLA typing are usually available within a few days, and healthcare providers will discuss the findings with the patient, particularly in the context of any relevant medical conditions or potential transplant considerations. It is important for patients to follow up with their healthcare provider to understand the implications of their HLA typing results and any necessary next steps.

Short Descr HLA TYPING DR/DQ
Medium Descr HLA TYPING DR/DQ SINGLE ANTIGEN
Long Descr HLA typing; DR/DQ, single antigen
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 1
CCS Clinical Classification 206 - Microscopic examination (bacterial smear, culture, toxicology)
91 Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient.
Date
Action
Notes
2011-01-01 Changed Short description changed.
Pre-1990 Added Code added.
Code
Description
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"